Optimizing Perioperative Care for Ventricular Tachycardia Ablation in High-Risk Patients Supported by Impella 5.5

Abstract

Impella 5.5 (Abiomed Inc., Danvers, MA, USA) is a surgically implanted mechanical circulatory support device that helps support hemodynamically compromised patients. The device's risks and benefits must be entirely known, especially in the electrophysiology lab. Due to unexpected hemodynamic changes during pace mapping and ablation, such as ventricular tachycardia (VT) and asystole, it is sometimes necessary to implement chemical support with inotropic agents such as epinephrine or mechanical support with devices such as an Impella. We present the case of a 72-year-old male with a biventricular implantable cardioverter-defibrillator (ICD) (Medtronic, Minneapolis, MN, USA) placed for refractory VT presenting for VT ablation. He had ischemic cardiomyopathy with a left ventricular ejection fraction (LVEF) of 33% and medical history of cardiac sarcoidosis, hypertension, hyperlipidemia, pulmonary embolism, left bundle branch block, and coronary artery disease. Due to the nature of the procedure and his history of arrhythmia, the patient was deemed a candidate for Impella 5.5. After evaluating patient risk factors, the cardiothoracic anesthesia team developed a strategic approach with imaging (including radiographic and echocardiographic imaging), Impella monitoring, and pharmacologic management with inotropes and vasopressors, allowing for uncomplicated perioperative management during the ablation. Given the procedure's intricacies and the patient's arrhythmia history, the medical team identified the patient as suitable for Impella 5.5 due to better performance and greater cardiac output than Impella 2.5 (Abiomed Inc., Danvers, MA, USA). Following a thorough assessment of the patient's risk factors, the cardiothoracic anesthesia team devised a comprehensive strategy to facilitate smooth perioperative management during the ablation, minimizing complications. The VT ablation procedure was performed successfully and effectively terminated the arrhythmia. However, the patient developed multifaceted postoperative complications, including cardiogenic shock, hemorrhagic shock, dyspnea, anemia, gastrointestinal abnormalities, and sepsis. This case represents a highly complex patient scenario under the care of the cardiovascular anesthesiologist due to the nature of the procedure and numerous cardiovascular comorbidities, low ejection fraction, ICD placement, and malignant ventricular arrhythmia. We discuss the various perioperative management strategies and how they are tailored to such patients, including pharmacologic intervention, anesthesia administration, imaging modalities, and postoperative care. The purpose of this case report is to delineate the role of Impella 5.5 in perioperative care for high-risk VT ablation patients. We discuss the progression, pathophysiology, and management of this patient's multisystem complications following the procedure. We also highlight the use of Impella 5.5 in the electrophysiology lab and the anesthesia considerations, safeguards, and management strategies ...